HUE058711T2 - Kromatográfiás oszlopos minõség-ellenõrzés anti-IL12/IL23 ellenanyag-készítmények elõállítására szolgáló gyártási eljárásokban - Google Patents

Kromatográfiás oszlopos minõség-ellenõrzés anti-IL12/IL23 ellenanyag-készítmények elõállítására szolgáló gyártási eljárásokban

Info

Publication number
HUE058711T2
HUE058711T2 HUE19722993A HUE19722993A HUE058711T2 HU E058711 T2 HUE058711 T2 HU E058711T2 HU E19722993 A HUE19722993 A HU E19722993A HU E19722993 A HUE19722993 A HU E19722993A HU E058711 T2 HUE058711 T2 HU E058711T2
Authority
HU
Hungary
Prior art keywords
manufacturing methods
chromatography column
antibody compositions
producing anti
column qualification
Prior art date
Application number
HUE19722993A
Other languages
English (en)
Inventor
Paul Randolph
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of HUE058711T2 publication Critical patent/HUE058711T2/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/50—Conditioning of the sorbent material or stationary liquid
    • G01N30/56—Packing methods or coating methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • B01D15/206—Packing or coating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8665—Signal analysis for calibrating the measuring apparatus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/00584—Control arrangements for automatic analysers
    • G01N35/00594—Quality control, including calibration or testing of components of the analyser
    • G01N35/00613—Quality control
    • G01N35/00623—Quality control of instruments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/50—Conditioning of the sorbent material or stationary liquid
    • G01N30/56—Packing methods or coating methods
    • G01N2030/562—Packing methods or coating methods packing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/889—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 monitoring the quality of the stationary phase; column performance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Quality & Reliability (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUE19722993A 2018-04-20 2019-04-19 Kromatográfiás oszlopos minõség-ellenõrzés anti-IL12/IL23 ellenanyag-készítmények elõállítására szolgáló gyártási eljárásokban HUE058711T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862660340P 2018-04-20 2018-04-20

Publications (1)

Publication Number Publication Date
HUE058711T2 true HUE058711T2 (hu) 2022-09-28

Family

ID=66429636

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE19722993A HUE058711T2 (hu) 2018-04-20 2019-04-19 Kromatográfiás oszlopos minõség-ellenõrzés anti-IL12/IL23 ellenanyag-készítmények elõállítására szolgáló gyártási eljárásokban

Country Status (21)

Country Link
US (5) US11079361B2 (hu)
EP (4) EP3781941A1 (hu)
JP (3) JP2021522477A (hu)
KR (3) KR20210003824A (hu)
CN (3) CN112313511A (hu)
AU (2) AU2019256647A1 (hu)
BR (2) BR112020021108A2 (hu)
CA (3) CA3097559A1 (hu)
DK (1) DK3781943T3 (hu)
EA (4) EA202192301A1 (hu)
ES (1) ES2914987T3 (hu)
HR (1) HRP20220676T1 (hu)
HU (1) HUE058711T2 (hu)
IL (2) IL278025B2 (hu)
LT (1) LT3781943T (hu)
PL (1) PL3781943T3 (hu)
PT (1) PT3781943T (hu)
RS (1) RS63424B1 (hu)
SG (1) SG11202010019YA (hu)
SI (1) SI3781943T1 (hu)
WO (3) WO2019204721A1 (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11567044B2 (en) * 2018-09-21 2023-01-31 Hitachi High-Tech Corporation Analysis device having a liquid chromatograph and method for analyzing a liquid chromatograph
WO2023194944A1 (en) * 2022-04-08 2023-10-12 Csl Behring Ag Methods of sanitizing and/or regenerating a chromatography medium
WO2024092203A1 (en) * 2022-10-28 2024-05-02 Amgen Inc. Compositions of anti-interleukin 12/interleukin 23 antibody
CN116369936B (zh) * 2023-05-31 2023-10-03 深圳市奋达智能技术有限公司 一种心电信号处理方法、系统、装置及存储介质
CN117907511B (zh) * 2024-03-20 2024-06-14 浙江灵析精仪科技发展有限公司 一种多组分重叠峰的自动化解析方法、装置及电子设备

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1353739A (fr) * 1963-03-06 1964-02-28 Gulf Research Development Co Appareil de chromatographie
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5410928A (en) 1993-10-27 1995-05-02 The Whitaker Corporation Scrap removal system for a stamping and forming machine
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
IL148898A0 (en) * 2000-07-28 2002-09-12 Euroflow Uk Ltd Methods and apparatus for packing chromatography columns and chromatography column
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US20070021277A1 (en) 2005-07-21 2007-01-25 Kuo Hai P Upper and lower body exerciser
CA2836123C (en) * 2005-12-20 2017-09-12 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US8833589B2 (en) 2005-12-21 2014-09-16 Pactiv Packaging Inc. Enhanced tamper evident bowl with blocked tab
DK2522717T3 (da) 2006-01-04 2014-04-22 Baxter Int Oligopeptid-frie cellekulturmedier
US20070215548A1 (en) 2006-01-05 2007-09-20 Zhou Joe Xin H Systems and methods for packing chromatography columns
KR20150064254A (ko) * 2006-04-05 2015-06-10 애브비 바이오테크놀로지 리미티드 항체 정제
US8028562B2 (en) * 2007-12-17 2011-10-04 Schlumberger Technology Corporation High pressure and high temperature chromatography
JP5728233B2 (ja) * 2008-01-25 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． クロマトグラフィーカラムの性能を監視するための自動化システムおよび方法、ならびにその応用
US20090277254A1 (en) * 2008-05-09 2009-11-12 Medlmmune, Llc Methods of improving packed-bed chromatography performance
CA2734246C (en) * 2008-08-15 2021-04-27 Biogen Idec Ma Inc. Methods for evaluating chromatography column performance
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
US7983852B2 (en) * 2008-10-21 2011-07-19 Thermo Finnigan Llc Methods of automated spectral peak detection and quantification without user input
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
CN102460147A (zh) * 2009-06-24 2012-05-16 弗·哈夫曼-拉罗切有限公司 可重复使用的色谱设备的鉴定
JP5651176B2 (ja) * 2009-08-20 2015-01-07 スペクトロセンス リミテッド ガスクロマトグラフ分析方法およびシステム
MX343328B (es) * 2009-10-26 2016-11-01 Nestec Sa Analisis para la deteccion de farmacos anti-tnf y anticuerpos.
WO2012084828A1 (en) 2010-12-21 2012-06-28 F. Hoffmann-La Roche Ag Chromatography equipment characterization
FR2973880B1 (fr) * 2011-04-06 2013-05-17 Commissariat Energie Atomique Procede et dispositif d'estimation de parametres biologiques ou chimiques dans un echantillon, procede d'aide au diagnostic correspondant
WO2013158279A1 (en) * 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
CN103163237B (zh) * 2013-02-03 2014-06-11 大连理工大学 获得有机化合物在碳纳米管上保留的热力学参数和吸附等温线的方法
EP2970865B1 (en) * 2013-03-15 2020-09-02 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
US10099156B2 (en) * 2013-04-08 2018-10-16 Chromacon Ag Chromatographic purification method
WO2015052721A1 (en) * 2013-10-09 2015-04-16 Spectrosense Ltd. Modified data representation in gas chromatographic analysis
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US10620172B2 (en) * 2014-11-17 2020-04-14 Ge Healthcare Bio-Sciences Ab Method and apparatus for performing liquid chromatography purification
FR3040215B1 (fr) * 2015-08-20 2019-05-31 Commissariat A L'energie Atomique Et Aux Energies Alternatives Procede d’estimation d’une quantite de particules reparties en classes, a partir d’un chromatogramme.
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
US20200347126A1 (en) * 2016-08-03 2020-11-05 Fyb 202 Project Gmbh Production of Biosimilar Ustekinumab In CHO Cells
KR20230119729A (ko) * 2016-10-25 2023-08-16 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템

Also Published As

Publication number Publication date
CN112313511A (zh) 2021-02-02
JP2021522477A (ja) 2021-08-30
SI3781943T1 (sl) 2022-07-29
EP3781943A1 (en) 2021-02-24
KR20210003824A (ko) 2021-01-12
US11079361B2 (en) 2021-08-03
ES2914987T3 (es) 2022-06-20
KR20210003830A (ko) 2021-01-12
HRP20220676T1 (hr) 2022-07-22
US20210332124A1 (en) 2021-10-28
IL278039A (en) 2020-11-30
CA3096902A1 (en) 2019-10-24
JP2021522204A (ja) 2021-08-30
PT3781943T (pt) 2022-08-05
CA3097559A1 (en) 2019-10-24
EA039041B1 (ru) 2021-11-25
EP3781943B1 (en) 2022-04-27
JP7344902B2 (ja) 2023-09-14
IL278025B2 (en) 2023-03-01
KR20210003825A (ko) 2021-01-12
CN112041674A (zh) 2020-12-04
US20190322736A1 (en) 2019-10-24
CN112041674B (zh) 2024-04-02
RS63424B1 (sr) 2022-08-31
EP3781941A1 (en) 2021-02-24
PL3781943T3 (pl) 2022-08-01
BR112020020480A2 (pt) 2021-01-12
EA202192300A1 (ru) 2022-03-31
WO2019204747A1 (en) 2019-10-24
CA3097776A1 (en) 2019-10-24
US20190321752A1 (en) 2019-10-24
EP3781942B1 (en) 2022-06-01
DK3781943T3 (da) 2022-06-20
IL278025A (en) 2020-11-30
AU2019256635A1 (en) 2020-10-15
US11225516B2 (en) 2022-01-18
LT3781943T (lt) 2022-07-11
CN112041673A (zh) 2020-12-04
EA202092510A1 (ru) 2020-12-22
SG11202010019YA (en) 2020-11-27
AU2019256647A1 (en) 2020-10-22
IL278025B (en) 2022-11-01
US20190324000A1 (en) 2019-10-24
WO2019204721A1 (en) 2019-10-24
US20220089716A1 (en) 2022-03-24
US12018075B2 (en) 2024-06-25
EA039018B1 (ru) 2021-11-23
JP2021522471A (ja) 2021-08-30
BR112020021108A2 (pt) 2021-02-17
EA202092511A1 (ru) 2020-12-29
EP4063850A1 (en) 2022-09-28
EP3781942A1 (en) 2021-02-24
WO2019204734A1 (en) 2019-10-24
JP7268054B2 (ja) 2023-05-02
EA202192301A1 (ru) 2022-03-31

Similar Documents

Publication Publication Date Title
IL278039A (en) Chromatography column training in production methods for the production of anti-IL12/IL23 antibody preparations
IL286314A (en) Production methods for the production of anti-il12/il23 antibody preparations
HK1257646A1 (zh) 包含雙特異性抗體建構物之醫藥組合物
CL2014001123A1 (es) Anticuerpos anti-il 36r; composicion farmaceutica que lo contiene; polinucleotido aislado que codifica el anticuerpo; metodo para la produccion del anticuerpo; kit de diagnostico que lo contiene.
EP3505538A4 (en) PROCESS FOR PRODUCING ANTIBODY FUSION PROTEIN
GB201406767D0 (en) Humanized anti-Tn-MUC1 antibodies anf their conjugates
SG11201707318PA (en) Method for detecting monoclonal antibody using mass spectrometry
EP3306310A4 (en) Method for quantifying monoclonal antibody
IL268470A (en) A method for producing multispecific antibodies
SG11202009036YA (en) Multivalent antibody
EP2995679A4 (en) PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES
EP3175242A4 (en) Quantifying monoclonal antibody therapeutics by lc-ms/ms
PT3735354T (pt) Métodos para fabricar painéis
IL286306A (en) Manufacturing methods for the production of anti-tnf antibody preparations
IL280278A (en) Preparations of FCRN antibodies
IL286307A (en) Methods for producing anti-tnf antibody preparations
PL3416983T3 (pl) Przeciwciała dla il-17c
PT3144676T (pt) Kit compreendendo anticorpo que se liga especificamente à proteína de fator b do complemento e anticorpo que se liga especificamente à proteína do antigénio carboidrato 19-9 para diagnosticar o cancro pancreático
HUE047867T2 (hu) Eljárás OSB elõállítására
IL286309A (en) Methods for producing anti-tnf antibody compositions
EP3492493A4 (en) METHOD FOR PRODUCING AN ANTIBODY FRAGMENT
PT3269521T (pt) Procedimento para manufactura de painéis em material de madeira
EP3668900A4 (en) METHOD OF ANTIBODY CONJUGATION
GB201820006D0 (en) Humanised anti-IL17BR antibody
EP3473274A4 (en) COMPOSITE ANTIBODY DRUG PLATFORM USING A BISPECIFIC ANTIBODY